

**Technology:** [Prostate-specific antigen-derived MHC class II restricted peptides and their use in vaccines to treat or prevent prostate cancer](#)

**VA ID Number:** 05-063

**Inventor:** Richard Alexander

**Location:** Baltimore, MD

**Topic:** Therapeutics/Oncology

**USPTO Issue Date:** 5/7/2013

**Patent Number:** 8,435,507

The VA has joint ownership with University of Maryland, Baltimore and Oregon Health & Science University

**Contact:** [christopher.drabik@va.gov](mailto:christopher.drabik@va.gov)

**Abstract:** The present invention relates to immunogenic peptides derived from human prostate cancer antigen (PSA-derived peptides) and their use as vaccines to treat or prevent prostate cancer. The invention is also related to dendritic cells from a patient having prostate cancer, which dendritic cells have been exposed to one or more PSA-derived peptides, and their use to treat or prevent prostate cancer in the patient. The invention is also directed to T-cells from a patient which cells are specific for PSA-activated peptide(s), and their uses to treat or prevent prostate cancer.